AORT Q4 Deep Dive: Stent Graft and On-X Growth Offset By Tissue Flatness, Guidance Highlights Pipeline

Medical device company Artivion (NYSE:AORT) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 19.2% year on year to $116 million. On the other hand, the company’s full-year revenue guidance of $495 million at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $0.17 per share was in line with analysts’ consensus estimates.

Is now the time to buy AORT? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Artivion’s fourth quarter results were met with a negative market reaction, as revenue came in just below Wall Street’s expectations. Management attributed the quarter’s performance to robust demand for stent grafts, which grew 36% year-over-year, and continued gains from the On-X mechanical heart valve, which benefited from newly published clinical data. CEO Pat Mackin noted, “Growth was driven by our continued global market share gains and early traction in our new $100 million U.S. market opportunity unlocked by recently published data.” However, tissue processing revenue remained subdued, reflecting lingering impacts from a prior cybersecurity incident, while BioGlue sales were flat due to distributor stocking variability.

Looking ahead, Artivion’s forward guidance is anchored by expectations for further expansion of its core stent graft and On-X platforms, as well as the potential impact of upcoming regulatory milestones. Management sees sustained double-digit revenue growth as achievable, underpinned by new clinical evidence and a planned ramp-up in marketing to cardiologists. Mackin explained, “We are investing in facilities, equipment, and systems to ensure we can efficiently support that growth over the long term,” pointing to ongoing clinical trials and new product launches as key levers for 2026 and beyond.

Key Insights from Management’s Remarks

Management cited accelerating adoption of stent grafts and On-X valves as major drivers, while tissue processing and BioGlue faced challenges from external events and market dynamics.

• Stent graft momentum: The stent graft portfolio saw significant growth, especially for the AMDS product in the U.S. and international markets. Management highlighted that 2025 was focused on account openings, with only about 10% of the target accounts currently onboarded, suggesting substantial runway for future growth as more hospitals adopt the technology.
• On-X valve expansion: On-X mechanical heart valve growth was fueled by global market share gains and new clinical studies supporting its use in patients under 65. Management emphasized early success in capturing a $100 million U.S. opportunity, noting positive feedback from referring cardiologists after data presentations.
• Tissue processing headwinds: Tissue processing revenue showed only modest improvement, remaining affected by lingering impacts from the previous year’s cybersecurity incident. Management expects this segment to remain flat in the coming year, reflecting both operational recovery and cautious planning.
• BioGlue sales variability: BioGlue performance was flat, with management explaining that quarter-to-quarter sales can fluctuate due to distributor stocking patterns rather than fundamental demand changes.
• Regional performance led by Asia Pacific: Asia Pacific revenues grew fastest among major geographies, with North America and EMEA also delivering double-digit growth. Management credited international expansion for bolstering overall company performance.

Drivers of Future Performance

Artivion expects continued double-digit revenue growth, driven by the scaling of stent graft and On-X platforms, but faces headwinds from flat tissue processing and rising R&D investment.

• AMDS and On-X as growth engines: Management believes further adoption of AMDS stent grafts and the On-X valve will be the primary contributors to revenue acceleration, supported by ongoing physician education and new clinical data. The company is focused on expanding into more accounts and increasing implant rates, particularly as On-X benefits from favorable reimbursement and differentiated clinical outcomes.
• Pipeline and regulatory milestones: Artivion is pursuing U.S. regulatory approvals for NEXUS and AMDS, with the former representing a $150 million potential market. Progress in the ARTISAN trial for the Arecibo LSA product is also expected to unlock additional market opportunities by 2029. Management noted that each new product approval could provide incremental growth and support the company’s target of a new PMA every two years.
• Margin expansion and investment: Expected margin improvements are tied to product mix and operating leverage, especially from higher-margin U.S. AMDS and On-X sales. However, R&D expenses will rise due to clinical trials, and capital expenditures will remain elevated to support manufacturing and IT infrastructure, which could temporarily limit EBITDA growth relative to revenue.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be monitoring (1) the rate of new account openings and implant growth for both AMDS and On-X, (2) progress on U.S. regulatory approvals for AMDS and NEXUS, and (3) the trajectory of tissue processing recovery and BioGlue sales stabilization. We will also watch for any acceleration in cardiologist education efforts and updates from the ARTISAN trial, as these may signal incremental upside to the growth outlook.

Artivion currently trades at $39.92, down from $40.65 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.